<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00647088</url>
  </required_header>
  <id_info>
    <org_study_id>P070141</org_study_id>
    <nct_id>NCT00647088</nct_id>
  </id_info>
  <brief_title>Genetic of Aortic Valve Stenosis - Clinical and Therapeutic Implications</brief_title>
  <acronym>GENERAC</acronym>
  <official_title>Genetic of Aortic Valve Stenosis - Clinical and Therapeutic Implications</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pathophysiology of Aortic Valve Stenosis remains poorly known. The aim of the present study
      is to identify genetic factors involved in this disease using a case control trial design.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aortic valve stenosis (AS) is the most common valvular disease and the second most common
      indication for cardiac surgery in Western countries. AS has long been considered as a passive
      and degenerative process. Recent data challenged this concept, showing that AS is an active
      and highly regulated process with some similarities to atherosclerosis. However,
      pathophysiology of AS remains poorly understood and preliminary data suggest that genetic
      factors may be involved. The aim of the present study is to identify genetic factors involved
      in this disease using a case control trial design (1000 patients with AS and 1500 controls
      with no evidence of valve disease). For all patients and controls, blood samples including
      DNA and echocardiography will be performed.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2008</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of genetic polymorphisms of fetuin-A, matrix-GLA protein, vitamin D receptor</measure>
    <time_frame>end of the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identification of other genetic polymorphisms</measure>
    <time_frame>End of the Study</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">2200</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <arm_group>
    <arm_group_label>aortic stenosis</arm_group_label>
    <description>various age and disease severity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>Controls free of valvular disease</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood samples DNA Tissue valve
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        case control study Case = patients with aortic valve stenosis Controls = participants free
        of aortic valve stenosis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Patients:

        Inclusion criteria :

          -  Age &gt;=18 years

          -  Pure isolated degenerative aortic valve stenosis

        Exclusion criteria :

          -  Rheumatic, congenital or post-radiation aortic stenosis

          -  Severe renal insufficiency (clearance &lt; 30 ml/min)

          -  Aortic insufficiency &gt; or = grade 2/4

          -  Other valve disease &gt; or = grade 2/4

        Controls

        Inclusion criteria :

        - Age &gt;=18 years

        Exclusion criteria :

          -  Known first degree relative with aortic valve stenosis

          -  Severe renal insufficiency (clearance &lt; 30 ml/min)

          -  Any valve disease &gt; or = grade 2/4
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Messika-Zeitoun, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Assistance Publique - Hôpitaux de Paris, Bichat Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David MESSIKA-ZEITOUN, MD</last_name>
      <phone>01 40 25 66 01</phone>
      <phone_ext>00 33</phone_ext>
      <email>david.messika-zeitoun@bch.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>David Messika-Zeitoun</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2008</study_first_submitted>
  <study_first_submitted_qc>March 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2008</study_first_posted>
  <last_update_submitted>February 27, 2017</last_update_submitted>
  <last_update_submitted_qc>February 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aortic Valve stenosis</keyword>
  <keyword>Genetic</keyword>
  <keyword>Mineralisation inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constriction, Pathologic</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

